FUNDC2

Across TCGA pan-cancer cohorts, FUNDC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FUNDC2 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FUNDC2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FUNDC2 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where FUNDC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.421	0.647	<.001	67	view →
CCRCC	DFS	Median	All	0.578	0.920	<.001	35	view →
GBM	DFS	Median	All	0.778	0.656	.024	10	view →
HNSC	OS	Median	All	0.809	0.625	.010	8	view →
LSCC	DFS	Tertile	III,IV	1.000	0.471	.033	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FUNDC2–PDAC (OS)

Open the PDAC breakdown →